Thematische Bibliographien / Cancer Radiotherapy

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Cancer Radiotherapy“

Autor: Grafiati
Veröffentlicht am 4. Juni 2021
Zuletzt aktualisiert am 29. Juli 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Cancer Radiotherapy" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Cancer Radiotherapy"

1

Sukarno, Vania, I. Widyadharma, Ida Wijayanti, Kumara Tini und Ngakan Ganapati. „Pain Characteristics of Cervical Cancer Patient Who Underwent Radiotherapy in Bali, Indonesia“. International Journal of Medical Reviews and Case Reports 4, Reports in Microbiology, Infecti (2020): 1. http://dx.doi.org/10.5455/ijmrcr.cervical-cancer-radiotherapy-bali.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Lee, B.-J., S.-G. Wang, H.-J. Roh, E.-K. Goh, K.-M. Chon und D.-Y. Park. „Changes in expression of p53, proliferating cell nuclear antigen and bcl-2 in recurrent laryngeal cancer after radiotherapy“. Journal of Laryngology & Otology 120, Nr. 7 (04.05.2006): 579–82. http://dx.doi.org/10.1017/s0022215106001150.

Der volle Inhalt der Quelle
Annotation:
The biological changes in recurrent laryngeal cancer following radiotherapy are not fully understood. The authors investigated differences in the expression of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 in laryngeal cancer specimens before radiotherapy and in recurrent laryngeal cancer specimens following radiotherapy in the same patients. The authors investigated the expression of p53, PCNA and bcl-2 by immunohistochemical stain in 30 specimens from 15 patients with primary laryngeal cancer and recurrent laryngeal cancer after radiotherapy.The expression of p53 protein was significantly different in laryngeal cancer before radiotherapy (4/15, 26.7 per cent) compared with recurrent laryngeal cancer after radiotherapy (8/15, 53.3 per cent) (p < 0.05). The PCNA index was also significantly different in laryngeal cancer specimens before radiotherapy (mean, 11.9 per cent) compared with recurrent laryngeal cancer after radiotherapy (mean, 18.0 per cent) (p < 0.05). However, there was no statistically significant alteration of bcl-2 expression in primary compared with recurrent laryngeal cancer. The expression of p53 and PCNA increased in recurrent laryngeal cancers after radiotherapy, compared with that in laryngeal cancers before radiotherapy. Recurrent laryngeal cancers arising following radiotherapy became biologically aggressive.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Mohamed Traore, Wend-Yam, Behyamet Onka, Ibrahima Dokal Diallo, Rachida Latib und Youssef Omor. „Post-radiotherapy recto-vaginal fistula in cervical cancer“. International Journal of Case Reports and Images 13, Nr. 2 (03.10.2022): 153–55. http://dx.doi.org/10.5348/101349z01wt2022ci.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Stepanović, Aleksandar, Tatjana Arsenijevic, Vesna Stankovic, Vukac Vujanac, Anja Lazovic, Tanja Raonic-Stevanovic und Marina Nikitovic. „Clinical analysis of COVID-19 positive cancer inpatients in National Cancer Center in Serbia“. Journal of Infection in Developing Countries 15, Nr. 09 (30.09.2021): 1286–92. http://dx.doi.org/10.3855/jidc.15104.

Der volle Inhalt der Quelle
Annotation:
Introduction: The outbreak of COVID-19 has had an impact on global healthcare as well as on radiotherapy practice in many countries. This study aimed to identify clinical characteristics of Coronavirus Disease 2019 (COVID-19) infected cancer inpatients, as well as what impact this infection had on radiation treatment of the patients. Methodology: In this retrospective study, we included cancer inpatients with laboratory confirmed COVID-19 infection during the radiotherapy or chemoradiation in April 2020 in National Cancer Research Center in Serbia. Data were obtained from the medical records between 1 April and 1 July 2020. Results: A total of 49 COVID-19 infected cancer inpatients were included. The most frequently reported cancers were head and neck cancers, in twenty-three patients (46.8%). Lymphopenia was present in 77.5% of the patients. Red blood cells, haemoglobin and platelets were significantly lower during incubation or diagnosis of COVID-19. Twenty-seven (55.1%) patients did not finish radiotherapy. The age of patients who finished radiotherapy after COVID-19 infection was significantly lower compared to the patients who did not finish radiotherapy (60.5 ± 7.8 vs. 68.6 ± 11.2; p < 0.005). Conclusions: COVID-19 infected cancer patients in radiotherapy practice show similar symptoms and demographic characteristics as the general population infected with SARS-CoV-2 virus. Patients with head and neck cancers may be susceptible to infection with COVID-19. Old age and male gender may be risk factors for discontinuation of radiotherapy in COVID-19 infected cancer patients.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Hsieh, Kristin, Daniel R. Dickstein, Juliana Runnels, Eric J. Lehrer, Kenneth Rosenzweig, Fred R. Hirsch und Robert M. Samstein. „Radiotherapy and Immunotherapy in Lung Cancer“. Biomedicines 11, Nr. 6 (06.06.2023): 1642. http://dx.doi.org/10.3390/biomedicines11061642.

Der volle Inhalt der Quelle
Annotation:
The emergence of immune checkpoint inhibitors (ICIs) as a pillar of cancer treatment has emphasized the immune system’s integral role in tumor control and progression through cancer immune surveillance. ICIs are being investigated and incorporated into the treatment paradigm for lung cancers across stages and histology. To date, definitive concurrent chemoradiotherapy followed by consolidative durvalumab is the only National Comprehensive Cancer Network’s recommended treatment paradigm including radiotherapy with ICI in lung cancers, although there are other recommendations for ICI with chemotherapy and/or surgery. This narrative review provides an overall view of the evolving integration and synergistic role of immunotherapy and radiotherapy and outlines the use of immunotherapy with radiotherapy for the management of small cell lung cancer and non-small cell lung cancer. It also reviews selected, practice-changing clinical trials that led to the current standard of care for lung cancers.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Pandey, Dr Vivek Kumar. „Prospective Study to Compare Outcomes Following Hypofractionated Radiotherapy versus Conventional Radiotherapy in Carcinoma Breast“. Journal of Medical Science And clinical Research 11, Nr. 07 (30.07.2023): 15–26. http://dx.doi.org/10.18535/jmscr/v11i7.04.

Der volle Inhalt der Quelle
Annotation:
Background: Breast cancer is now the most common cancer worldwide (GLOBOCAN, 2020). It is the most common cancer among women in developed countries. The age standardized incidence rate of breast cancer in India is 25.8% per 100,000 women (GLOBOCAN, 2020). By 2020, breast cancer overtook cervical cancer as the most common type of cancer among all women in India. Breast irradiation has been shown to reduce the risk of local recurrence after breast-conserving surgery from about 30% to <10% at 10 years. Aims & Objectives: Randomize Breast carcinoma into two arms - Arm A :- 39GY in 13 fractions over 2.3 weeks & Arm B:- 50 GY in 25 fractions over 5weeks. Compare locoregional response in two arms 4 weeks after completion of radiation therapy and at the end of six months of follow up. Compare acute and chronic toxicities in the two arms.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Manzoor, Najmi Arshad. „Unplanned Interruption of Radiotherapy in Head and Neck Cancers: report from a Regional Cancer Centre“. Journal of Medical Science And clinical Research 05, Nr. 04 (14.04.2017): 20294–300. http://dx.doi.org/10.18535/jmscr/v5i4.90.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Rovirosa, Angeles, Meritxell Arenas und Luca Tagliaferri. „Interventional Radiotherapy in Gynecological Cancer“. Cancers 15, Nr. 19 (29.09.2023): 4804. http://dx.doi.org/10.3390/cancers15194804.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Chandra, Ade, Sukri Rahman, Al Hafiz, Eva Decroli und Hafni Bachtiar. „Pengaruh Radioterapi Terhadap Kadar TSH dan T4 pada Pasien Tumor Ganas Kepala dan Leher“. Oto Rhino Laryngologica Indonesiana 48, Nr. 2 (30.01.2019): 159. http://dx.doi.org/10.32637/orli.v48i2.238.

Der volle Inhalt der Quelle
Annotation:
Latar belakang: Tumor ganas kepala dan leher adalah tumor ganas yang berasal dari epitel traktus aerodigestif atas. Radioterapi adalah salah satu modalitas talaksana pada tumor ganas kepala dan leher. Kelenjar tiroid akan terpapar radioterapi selanjutnya merangsang terjadinya kelainan pada kelenjar tiroid. Hipotiroid merupakan efek samping yang paling umum terjadi akibat radioterapi. Diagnosis hipotiroid ditegakkan melalui pemeriksaan laboratorium yaitu didapatkan peningkatan TSH dan penurunan T4. Tujuan: Mengetahui pengaruh radioterapi terhadap kadar TSH dan T4 pasien tumor ganas kepala dan leher di RSUP Dr. M. Djamil, Padang. Metode: Analitik cross sectional dengan desian pre and post test only pada 10 responden tumor ganas kepala dan leher. Sampel berupa darah vena yang dihitung kadar TSH dan T4 menggunakan alat Vidas 3. Data dianalisis dengan uji t berpasangan. Hasil analisis statistik dinyatakan bermakna bila didapatkan hasil p<0,05. Hasil: Nilai rerata kadar TSH sebelum dan setelah radioterapi didapatkan 0,57 ± 0,512 µIU/ml. Nilai rerata kadar T4 sebelum dan setelah radioterapi didapatkan 0,721 ± 0,508 µg/dL. Uji t bepasangan didapatkan peningkatan rerata kadar TSH setelah radioterapi dengan p = 0,004 yang menunjukkan peningkatan bermakna rerata kadar TSH setelah radioterapi dan didapatkan penurunan rerata kadar T4 setelah radioterapi dengan p = 0,001 yang menunjukkan penurunan bermakna rerata kadar T4 setelah radioterapi. Kesimpulan: Terdapat peningkatan bermakna rerata kadar TSH serta penurunan rerata kadar T4 sebelum dan setelah radioterapi pada pasien tumor ganas kepala dan leher walau belum melewati nilai normal.ABSTARCTBackground: Head and neck cancers are malignancies that originate from upper aerodigestive tract epithelium. Radiotherapy is one of the modalities treatments for head and neck cancer. Thyroid glands which exposed by radiotherapy, furthermore can induce abnormalities. Hypothyroid is a most common abnormality that occur after radiotherapy. Diagnosis hypothyroidism can be established through laboratory examination that is obtained an increased levels of TSH and decreased levels of T4. Purpose: To determine effect radiotherapy on levels of TSH and T4 in patients with head and neck cancer in Dr. M. Djamil Hospital, Padang. Methods: Cross sectional analytic study with pre and post test only on 10 respondents with head and neck cancer. Samples taken from venous blood then TSH and T4 were counted with Vidas 3. Data was analyzed with paired t-test. The statistical result was significant with p<0,05. Result: Mean value of TSH before and after radiotherapy is 0,57 ± 0,512 µUI/ml. Mean value of T4 before and after radiotherapy is 0,721 ± 0,508 µg/dL. From paired t-test resulted an increase of TSH mean value after radiotheraphy with p = 0,004 which implies a significant enhancement of TSH mean value after radiotheraphy and decreasing T4 mean value after radiotheraphy with p = 0,001 which implies a significant deflation of T4 mean value after radiotheraphy. Conclusions: There was significant enhancement of TSH mean and significant deflation of T4 mean value before and after radiotherapy on patients with head and neck cancer even still within normal value. Keywords: Radiotheraphy, TSH, T4, head and neck cancer.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Shirai, Katsuyuki, Akiko Nakagawa, Takanori Abe, Masahiro Kawahara, Jun-ichi Saitoh, Tatsuya Ohno und Takashi Nakano. „Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers“. International Journal of Molecular Imaging 2012 (14.05.2012): 1–9. http://dx.doi.org/10.1155/2012/609545.

Der volle Inhalt der Quelle
Annotation:
Radiotherapy plays an important role in the treatment for thoracic cancers. Accurate diagnosis is essential to correctly perform curative radiotherapy. Tumor delineation is also important to prevent geographic misses in radiotherapy planning. Currently, planning is based on computed tomography (CT) imaging when radiation oncologists manually contour the tumor, and this practice often induces interobserver variability. F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been reported to enable accurate staging and detect tumor extension in several thoracic cancers, such as lung cancer and esophageal cancer. FDG-PET imaging has many potential advantages in radiotherapy planning for these cancers, because it can add biological information to conventional anatomical images and decrease the inter-observer variability. FDG-PET improves radiotherapy volume and enables dose escalation without causing severe side effects, especially in lung cancer patients. The main advantage of FDG-PET for esophageal cancer patients is the detection of unrecognized lymph node or distal metastases. However, automatic delineation by FDG-PET is still controversial in these tumors, despite the initial expectations. We will review the role of FDG-PET in radiotherapy for thoracic cancers, including lung cancer and esophageal cancer.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Cancer Radiotherapy"

1

Mairs, Robert J. „Targeted radiotherapy of cancer“. Thesis, University of Glasgow, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248190.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Radu, Calin. „Optimising Radiotherapy in Rectal Cancer Patients“. Doctoral thesis, Uppsala universitet, Enheten för onkologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172531.

Der volle Inhalt der Quelle
Annotation:
Rectal cancer is the eight most common cancer diagnosis in Sweden in both men and women, with almost 2000 new cases per year. Radiotherapy, which is an important treatment modality for rectal cancer, has evolved during the past decades. Diagnostic tools have also improved, allowing better staging and offering information used to make well-founded decisions in multidisciplinary team conferences. In a retrospective study (n=46) with locally advanced rectal cancer (LARC) patients, unfit for chemoradiotherapy, patients were treated with short-course radiotherapy. Delayed surgery was done when possible. Radical surgery was possible in 89% of the patients who underwent surgery (80%). Grade IV diarrhoea affected three elderly patients. Target radiation volume should be reduced in elderly or metastatic patients. In a prospective study (n=68) with LARC patients, magnetic resonance imaging (MRI) and 2-18F-fluoro-2-D-deoxyglucose (FDG) positron emission tomography (PET) were used to determine if FDG-PET could provide extra treatment information. Information from FDG-PET changed the stage of 10 patients. Delineation with FDG-PET generally resulted in smaller target volumes than MRI only. Seven of the most advanced LARC patients in the above cohort were used for a methodological study to determine if dose escalation to peripheral, non-resectable regions was feasible. Simultaneous integrated boost plans with photons and protons were evaluated. While toxicity was acceptable in five patients with both protons and photons, two patients with very large tumours had unacceptable risk for intestinal toxicity regardless of modality. In the interim analysis of the Stockholm III Trial (n=303, studying radiotherapy-fractionation and timing of surgery in relation to radiotherapy) compliance was acceptable and severe acute toxicity was infrequent, irrespective of fractionation. Short-course radiotherapy with immediate surgery tended to give more postoperative complications, but only if surgery was delayed more than 10 days after the start of radiotherapy. Quality-of-life in the Stockholm III Trial was studied before, during and shortly after treatment using the EORTC QLQ-C30 and CR38 questionnaires. Surgery accounted for more adverse effects than radiotherapy in all groups. Postoperatively, the poorest quality-of-life was seen in patients given short-course radiotherapy followed by immediate surgery. No postoperative differences were seen between the two groups with delayed surgery.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Martling, Anna. „Rectal cancer : staging, radiotherapy and surgery /“. Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-461-5/.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Langlands, Fiona Elizabeth. „Sensitivity to radiotherapy in breast cancer“. Thesis, University of Leeds, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.582111.

Der volle Inhalt der Quelle
Annotation:
Radiotherapy (RT) is a component of treatment for breast cancer in more than 50% of cases. Patients are selected for RT on the basis of limited clinical and histopathological factors with no reference to the molecular phenotype of tumours. Breast cancer is a highly heterogeneous disease and some tumours are refractory to RT treatment. Selection of patients for RT using predictive markers may improve RT efficacy and cancer outcomes. The aims of the work described in this thesis were to identify and test potential predictive markers for RT in cancer treatment. I examined whether the classic histopathological breast cancer subtypes or the levels of expression of five molecular markers, 26S proteasome, GRP78, HJURP, IGFlR and PARPl, would provide predictive insights into response to RT in the context of both cultured breast cancer cell lines, and archival patient samples supported by clinical follow up. Clonogenic survival assays revealed that cell lines representative of luminal or basal breast cancers did not display subtype specific responses to RT. Similarly, expression levels of 26S proteasome, GRP78, HJURP, IGFlR and PARPl did. not correlate with specific responses to RT in cell lines. In breast cancer patients who underwent RT high expression of 26S proteasome was significantly associated with increased rates of local recurrence. High expression of HJURP was associated with reduced rates of local recurrence, as was high expression of PARPl. Importantly, these associations were not found in patients who were treated without RT, suggesting that these markers provide predictive in sights into RT response, rather than prognostic insights into the likelihood of local recurrence overall. Finally, high expression of 26S proteasome was also found to be associated with increased rates of local recurrence in bladder cancer patients, suggesting that this marker may have predictive value for RT in a range of cancer settings.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Taylor, Carolyn W. „Breast cancer radiotherapy and heart disease“. Thesis, University of Oxford, 2008. http://ora.ox.ac.uk/objects/uuid:c9dda3ca-8cb3-4a38-938d-0b75b4f6471d.

Der volle Inhalt der Quelle
Annotation:
Introduction: Some past breast cancer radiotherapy regimens led to an increased risk of death from heart disease. Although heart dose from breast cancer radiotherapy has generally reduced over the past few decades, there may still be some cardiac risk. Estimation of future risk for women irradiated today requires both measurement of their cardiac dose and dose-response relationships, which depend on cardiac dosimetry of past regimens, in conjunction with long-term follow-up data. Methods: Virtual simulation and computed tomography 3-dimensional treatment planning on a representative patient were used to estimate mean heart and coronary artery doses for women irradiated since 1950 in 71 randomised trials in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) overview. Patient-to-patient variability in cardiac dose was assessed. Heart and coronary artery doses were also calculated for breast cancer radiotherapy regimens used since the 1950s in Sweden. Cardiac doses from contemporary (year 2006) radiotherapy were assessed for 55 patients who received tangential breast cancer irradiation at a large UK radiotherapy centre. The maximum heart distance (i.e. the maximum distance between the anterior cardiac contour and the posterior tangential field edges) was measured for the left-sided patients, and its value as a predictor of cardiac doses assessed. Results: Mean heart dose for women irradiated in the EBCTCG trials varied from <1 to 18 Gray, and mean coronary artery dose from <1 to 57 Gray. Patient-to-patient variability was moderate. Mean heart dose for women irradiated in Sweden since the 1950s varied from <1 to 24 Gray, and mean coronary artery dose from <1 to 46 Gray. Heart dose from tangential irradiation has reduced over the past four decades. However, mean heart dose for left-sided patients irradiated in 2006 was 2 Gray and around half of them still received >20 Gray to parts of the heart and left anterior descending coronary artery. For these patients, maximum heart distance was a reliable predictor of cardiac doses. For the other patients, mean heart dose varied little and was usually less than 2 Gray. Conclusions: Cardiac doses from breast cancer radiotherapy can be estimated reliably and are now available for use in deriving dose-response relationships in the EBCTCG data and in a Scandinavian case-control study. Cardiac dose has reduced over the past four decades. Therefore the cardiac risk is also likely to have reduced. Nevertheless, for some patients, parts of the heart still receive >20 Gray in the year 2006.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

吳曉靑 und Xiaoqing Wu. „Post-radiotherapy cervical metastasis in nasopharyngeal carcinoma“. Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1999. http://hub.hku.hk/bib/B31222018.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Cheng, Kun. „Deformable models for adaptive radiotherapy planning“. Thesis, University of Edinburgh, 2016. http://hdl.handle.net/1842/22893.

Der volle Inhalt der Quelle
Annotation:
Radiotherapy is the most widely used treatment for cancer, with 4 out of 10 cancer patients receiving radiotherapy as part of their treatment. The delineation of gross tumour volume (GTV) is crucial in the treatment of radiotherapy. An automatic contouring system would be beneficial in radiotherapy planning in order to generate objective, accurate and reproducible GTV contours. Image guided radiotherapy (IGRT) acquires patient images just before treatment delivery to allow any necessary positional correction. Consequently, real-time contouring system provides an opportunity to adopt radiotherapy on the treatment day. In this thesis, freely deformable models (FDM) and shape constrained deformable models (SCDMs) were used to automatically delineate the GTV for brain cancer and prostate cancer. Level set method (LSM) is a typical FDM which was used to contour glioma on brain MRI. A series of low level image segmentation methodologies are cascaded to form a case-wise fully automatic initialisation pipeline for the level set function. Dice similarity coefficients (DSCs) were used to evaluate the contours. Results shown a good agreement between clinical contours and LSM contours, in 93% of cases the DSCs was found to be between 60% and 80%. The second significant contribution is a novel development to the active shape model (ASM), a profile feature was selected from pre-computed texture features by minimising the Mahalanobis distance (MD) to obtain the most distinct feature for each landmark, instead of conventional image intensity. A new group-wise registration scheme was applied to solve the correspondence definition within the training data. This ASM model was used to delineated prostate GTV on CT. DSCs for this case was found between 0.75 and 0.91 with the mean DSC 0.81. The last contribution is a fully automatic active appearance model (AAM) which captures image appearance near the GTV boundary. The image appearance of inner GTV was discarded to spare the potential disruption caused by brachytherapy seeds or gold markers. This model outperforms conventional AAM at the prostate base and apex region by involving surround organs. The overall mean DSC for this case is 0.85.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Taylor, Alexandra. „Intensity-modulated radiotherapy for cervical cancer : optimising target volume definition and radiotherapy delivery“. Thesis, University of London, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.510901.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Murphy, Caroline Claire Scanlon. „A history of radiotherapy to 1950 : cancer and radiotherapy in Britain 1850-1950“. Thesis, University of Manchester, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.278710.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Riekki, R. (Riitta). „Late dermal effects of breast cancer radiotherapy“. Doctoral thesis, University of Oulu, 2006. http://urn.fi/urn:isbn:9514282760.

Der volle Inhalt der Quelle
Annotation:
Abstract Radiotherapy is used in the treatment of breast cancer in order to reduce local recurrence rate. However, radiation is known to cause both acute and delayed side-effects on normal tissues. A common late complication of radiotherapy is fibrosis of skin and other organs. Fibrosis has been described as excessive accumulation of extracellular matrix components, especially collagens. Collagens are a group of extracellular matrix proteins that provide connective tissues with tensile strength. Type I and III collagens are the major structural proteins in skin. Alterations in collagen synthesis occur in various pathological conditions, during ageing and in association with diverse medical therapies. Collagens are degraded by matrix metalloproteinase enzymes (MMPs). The activity of MMPs is restrained by their specific tissue inhibitors (TIMPs). Elastic fibres constitute about 2–4% of skin dry weight. Despite their low quantity, elastic fibres are responsible for the resilient and elastic properties of skin. Dermal elastic fibres may be affected by intrinsic ageing, by extrinsic reasons such as photodamage and in several connective tissue diseases. The effect of radiotherapy on human skin type I and III collagen synthesis was investigated in a group of women who had been treated for breast cancer surgically and with radiotherapy. The levels of MMP-9, MMP-2/TIMP-2 complex, TIMP-1 and TIMP-2 in irradiated skin were also analysed. The effect of radiotherapy on elastic fibres was analysed using skin samples. The physio-mechanical properties of radiotherapy-treated skin were studied using ultrasound and elastometer devices, and compared with those of non-treated skin. In addition, skin samples were stained for haematoxylin-eosin, tenascin and mast cells. Factor VIII immunostaining was performed to visualize dermal blood vessels. Wound regeneration in irradiated skin was also studied using suction blister as a model. The synthesis of type I and III collagens was markedly increased as a result of radiotherapy. An increased amount of cross-linked type I collagen was detected in irradiated skin, and collagen turnover was also increased in irradiated skin. No difference in the amount or structure of the elastic fibres could be found between radiotherapy-treated and non-treated skin. A slight increase of skin thickness and stiffness was found in irradiated skin compared to non-treated skin. Increased tenascin expression was found in irradiated skin. The number of dermal blood vessels visualized by FVIII immunostaining was slightly higher in irradiated than in control skin. The amount of mast cells positive for tryptase, Kit receptor and chymase was increased in the upper dermis of irradiated skin. No difference in epidermal regeneration was found between irradiated and non-treated skin. The results of this study suggest that alteration of collagen metabolism contributes to dermal side effects of therapeutic irradiation.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Cancer Radiotherapy"

1

Seong, Jinsil, Hrsg. Radiotherapy of Liver Cancer. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-1815-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Geinitz, Hans, Mack Roach III und Nicholas van As, Hrsg. Radiotherapy in Prostate Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-37099-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Joseph, Kurian Jones, Michael J. Veness, Elizabeth Barnes und Agata Rembielak, Hrsg. Radiotherapy in Skin Cancer. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-44316-9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Carlo, Greco, und Zelefsky Michael, Hrsg. Radiotherapy of prostate cancer. Australia: Harwood Academic, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

International Cancer Research Data Bank., Hrsg. Intraoperative radiotherapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Rich, Tyvin A. Intraoperative radiotherapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Priestman, Terry J. Coping with radiotherapy. London: Sheldon Press, 2007.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Organization, World Health, Hrsg. Radiotherapy in cancer management: A practical manual. London: Chapman & Hall Medical, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Marcu, Loredana, Eva Bezak und Barry Allen. Biomedical Physics in Radiotherapy for Cancer. London: Springer London, 2012. http://dx.doi.org/10.1007/978-0-85729-733-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

1938-, Cox James D., Chang Joe Y und Komaki Ritsuko, Hrsg. Image-guided radiotherapy of lung cancer. New York: Informa Healthcare, 2008.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Cancer Radiotherapy"

1

Parker, Kate, Ann Maloney und Debbie Wyatt. „Radiotherapy“. In Cancer and Cancer Care, 194–216. 1 Oliver’s Yard, 55 City Road London EC1Y 1SP: SAGE Publications Ltd, 2015. http://dx.doi.org/10.4135/9781473920620.n13.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Veronesi, Umberto. „Radiotherapy“. In Breast Cancer, 46–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76054-9_7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Takayama, Kanako, Yusuke Demizu und Nobukazu Fuwa. „Radiotherapy“. In Oral Cancer, 285–306. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-54938-3_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Cozma, Adrian, Maitry Patel, Edward Chow und Srinivas Raman. „Cancer: Radiotherapy“. In Textbook of Palliative Medicine and Supportive Care, 623–38. 3. Aufl. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9780429275524-65.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Calvo, Felipe A., Oscar Abuchaibe, Javier Aristu, Javier Zudiare und José María Berián. „Bladder Cancer“. In Intraoperative Radiotherapy, 73–78. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_10.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Calvo, Felipe A., David Ortiz de Urbina, Fernando de la Fuente, Matias Jurado und José María Berián. „Gynecologic Cancer“. In Intraoperative Radiotherapy, 79–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Calvo, Felipe A., David Ortiz de Urbina, Jesús Herreros und Rafael Llorens. „Lung Cancer“. In Intraoperative Radiotherapy, 43–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Calvo, Felipe A., Manuel Santos, Fernando Pardo, José L. Hernández, Javier Alvarez-Cienfuegos und Juan Voltas. „Gastric Cancer“. In Intraoperative Radiotherapy, 51–56. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Calvo, Felipe A., Ignacio Azinovic, Gerardo Zornoza, Juan Voltas, Fernando Pardo und Javier Alvarez-Cienfuegos. „Pancreatic Cancer“. In Intraoperative Radiotherapy, 57–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Calvo, Felipe A., Ignacio Azinovic, Fernando Pardo, José L. Hernández und Javier Alvarez-Cienfuegos. „Colorectal Cancer“. In Intraoperative Radiotherapy, 65–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Cancer Radiotherapy"

1

Mason, Suzie, Yiannis Roussakis, Rongxiao Zhang, Geoff Heyes, Gareth Webster, Stuart Green, Brian Pogue und Hamid Dehghani. „Cherenkov Radiation Portal Imaging during Photon Radiotherapy“. In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jm3a.41.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Bax, Maria Luiza de Oliveira Almeida, Clécio Ênio Murta de Lucena, Calliny Cristina Pimentel Alves und Matheus Assis dos Anjos Bastos Oliveira. „BREAST RECONSTRUCTION WITH AND WITHOUT ADJUVANT RADIOTHERAPY: A CRITICAL REVIEW“. In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2067.

Der volle Inhalt der Quelle
Annotation:
Objective: Breast cancer is the most common malignancy in women worldwide. After mastectomy, many women wish to reconstruct the affected breast, and immediate breast reconstruction has proven to be oncologically safe in relation to just mastectomy. In addition, indications for post-mastectomy radiotherapy (PMRT) sessions are becoming more frequent, due to their relationship with reduced mortality and locoregional recurrence. For this reason, many women who opted for immediate reconstruction underwent radiotherapy with implants or expanders. This study aims to compare the outcomes of patients with breast cancer undergoing adjuvant radiotherapy after breast reconstruction surgery with an implant or expander with patients who did not need irradiation. Methods: A literature review was carried out on the CAPES Journal Portal. Results: The studies are unanimous when it comes to the increased risk of complications between the control groups and patients who have undergone PMRT. The reconstructive failure rates are lower, and the aesthetic results are better in surgeries with implants when compared with tissue expanders. Autologous surgeries are apparently safe and should be considered in the context of the PMRT. Conclusion: This review did not find sufficient scientific evidence to determine the best technique and the best period for radiotherapy in PMRT indications. It is concluded that the choice of the operative technique and the time of radiotherapy must be at the discretion of the surgeon and the multidisciplinary team of each service, always in a shared decision with the patient.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Demeshko, P. D., A. N. Batyan und E. V. Hancharova. „METHODS FOR EVALUATING LONG-TERM RESULTS OF RADIOTHERAPY FOR CANCER WITH HIGH AND LOW PROLIFERATION POTENTIAL“. In SAKHAROV READINGS 2021: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute, 2021. http://dx.doi.org/10.46646/sakh-2021-1-249-252.

Der volle Inhalt der Quelle
Annotation:
The quality of radiation treatment for oncological diseases can be influenced by a large number of factors. Among them, the breaks that occur during the course of radiotherapy play an important role. Split courses of radiotherapy are used in the practice of radiation treatment of head and neck cancer, as well as prostate cancer. Breaks between the stages of the course of radiotherapy lasting 1-2 weeks are carried out in elderly, debilitated patients or in the presence of radiation reactions of 3-4 degrees. Before the start of radiotherapy, a set of measures is taken to prevent radiation reactions. This can affect the fact that the course of radiotherapy will be carried out without interruption. Using Cox regression, it is proposed to evaluate the effect of interruptions in the course of radiotherapy on the outcome of treatment for head and neck tumors, as well as the prostate tumors taking into account the observation period.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Meyer, Bianca dos Santos, Lélisa Pereira Oliveira, Carlos Antônio da Silva Franca, Reynaldo Real Martins Júnior und Antônio Belmiro Rodrigues Campbell Penna. „IMPACT OF DELAYED ADJUVANT RADIOTHERAPY ON BREAST CANCER“. In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1044.

Der volle Inhalt der Quelle
Annotation:
Introduction: In documents from the Brazilian Society of Radiotherapy, quantitative analysis revealed that radiotherapy sessions, when performed, have not been timely. The average waiting time between the diagnosis data and the start of radiotherapy has been, on average, 113.4 days — which can consistently affect the chances of being cured for many patients. In some regions, waiting time is even longer; not infrequently, patients are treated with outdated methods and unprecision machines. Radiotherapy in Brazil is in a critical situation, especially with regard to the care of patients assisted by the Brazilian Public Health System (SUS). The main problems that contribute to this scenario are related to inadequate description and poor installation capacity, both from the point of view of the number of devices and their geographic distribution. Objective: The aim of this study was to determine whether delaying the initiation of adjuvant radiotherapy is related to decreased survival in women with breast cancer. Methods: This is a retrospective, descriptive, and longitudinal study (cross section) of patients admitted to the CRI/IBO, Niterói, RJ, all from SUS. Through the review of medical records, 81 patients were selected. Only patients diagnosed with stage IIb (T3N0) breast malignancy according to the American Joint Committee on Cancer TNM 8th (AJCC) were included. The analysis was performed by the time taken to start the radiotherapy after the initial treatment, which was treated by conservative surgery followed by adjuvant chemotherapy. The cohort was divided into two groups according to the timing of radiotherapy after the initial treatment: 6 months. Results: In the data analysis, it was observed that 70 (86.4%) patients did not have disease recurrence, while 11 (13.6%) patients had tumor recurrence. The average time between the end of the last chemotherapy day and the start of adjuvant radiotherapy was 6.1 months (1–12/95%CI 5.5–6.8, SD±2.9). Referring patients to those who provide adjuvant radiotherapy at 6 months (group B), we have 36 patients (44.4%) in group A and 45 patients (55.6%) in group B. In group A (36 patients), 34 patients (94.4%) did not have tumor recurrence and 2 (5.6%) did have tumor recurrence. In group B (45 patients), 36 (80%) patients did not have tumor recurrence and 9 (20%) did have tumor recurrence, with p=0.0001. Bearing in mind that the objective of the study is disease-free survival in 5 years, the mean follow-up time of patients was 69.8 months (51–92/95%CI 68.2–71.3, SD±7.0). It was evaluated that patients who had adjuvant radiotherapy in less than 6 months had a longer survival than patients who had more than 6 months (p <0.001). Therefore, patients with a delay of more than 6 months in the initial adjuvant radiotherapy treatment had an impact on the 5-year disease-free survival. Conclusion: This study is not conclusive, but we were able to observe data that show a worsening in the patient’s survival and prognosis in relation to the delay in the radiotherapy treatment. However, the waiting time for radiotherapy should be as short as reasonably possible, as there is a possibility that this delay will cause worse disease control rates.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Ferraz, Lara Cristina, Ana Carolina da Silva França Gomes, Juliana Teixeira Mendes, Angela Cristina Marinho Moreira, Antonio Belmiro Rodrigues Campbell Penna, Carla Nogueira, Reynaldo Real Martins Júnior und Carlos Antonio da Silva Franca. „Serum hemoglobin and relation to the staging of patients with breast cancer before the start of radical radiotherapy“. In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1038.

Der volle Inhalt der Quelle
Annotation:
Introduction: Among cancers, breast cancer is the leading cause of death from cancer in Brazilian women, second only to lung cancer worldwide. Few data are available in the literature portraying the prevalence of lower hemoglobin levels in cancer patients, especially if related to a worse prognosis with a more aggressive disease. Therefore, scientific studies are needed to make the relationship with such a pathology consistent. Objective: The objective of this study was to assess serum hemoglobin levels and whether this is associated with worse staging in patients with breast cancer indicated for radiotherapy treatment. Methodology: This is a prospective, descriptive, and longitudinal study with patients with breast cancer referred for radical radiotherapy, through the evaluation of blood hemoglobin and its initial staging. Results: We evaluated 40 patients with a mean age of 63.7 years (30–81/95%CI 60.4–67/SD±10.3). Mean serum hemoglobin was 12.6 g/dl (9–15.3/95%CI 12.1–13.1/SD±1.4). Four (10%) patients stage Ia, 9 (22.5%) stage Ib, 9 (22.5%) stage IIa, 11 (27.5%) stage IIB, and 7 (17.5%) stage IIIa were observed. A cohort study was conducted on patients, classifying them into group 1 with 13 patients (32.5% — stages Ia and Ib), group 2 with 20 patients (50% — stages IIa and IIb), and group 3 with 7 patients (17.5% — stage IIIa). The mean hemoglobin in group 1 was 13.9 g/dl (95%CI 13.4–14.4/SD±0.9), mean hemoglobin in group 2 was 12.5 g/dl (95%CI 12.3–12.7/SD±0.5), and in group 3, mean hemoglobin was 10.4 g/dl (95%CI 9.3–11.5/ SD±1.2) (p <0.001), demonstrating the existence of a statistically important relationship between worse staging and lower plasma hemoglobin levels. Conclusion: Patients with a worse prognosis may have lower plasma hemoglobin levels, which may demonstrate greater tumor aggressiveness in these patients.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Ferreira, Rubens Rezende, Luan Almeida Japiassu de Freitas Queiroz, Sabrina Rocha Medeiros, Sara Leite Lira Santos, Carolina Gabriela Divino Soares Gioia, Victor Filipi Lemes Fernandes, Fernando Santos Azevedo und Ana Flávia de Paula G. Campedelli. „Radiotherapy and breast cancer: The risks of malignancies secondary to breast cancer treatment in patients with Li-Fraumeni syndrome“. In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1087.

Der volle Inhalt der Quelle
Annotation:
Objective: This study aimed to highlight the risks of malignancy induced by radiotherapy in the treatment of patients with breast cancer with Li-Fraumeni syndrome. Methodology: To this end, a literature review was carried out in the PubMed scientific database, using the descriptors: “Li-Fraumeni syndrome,” “TP53 gene,” and “Malignancies secondary to radiotherapy,” and as inclusion criteria, it was used: works in Portuguese and English, not duplicated and between the years 2016–2023, with the intention of using the most recent sources for the search result. Results: DNA damage by ionizing radiation is the main mechanism of radiotherapy action; therefore, disturbances in DNA repair can result in increased sensitivity to cancer treatment recessive radiosensitivity, for example, in patients with Li-Fraumeni syndrome. This is an autosomal dominant inherited disease that is usually associated with abnormalities in the P53 tumor suppressor protein (TP53) gene, located on chromosome 17p13. That said, the risk of malignancies correlates with the type of TP53 germline pathogenic variant, with the TP53 p.R337H mutation being particularly prevalent in Brazil. According to a published study in the journal Breast Cancer Research and Treatment, the risk of radiation-induced malignancy associated with Li-Fraumeni syndrome was higher for sarcoma and thyroid cancer in 12% of patients studied. Conclusion: Thus, when initiating radiotherapy treatment, early molecular diagnosis, with the intention of finding the Li-Fraumani syndrome, and careful assessment of the risks and benefits of treatment are essential for these patients, considering that the physician must always care for the well-being of the patient and, above all, do not cause harm to the patient.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Leonard, CE, RD Sobus, S. Fryman, S. Sedlacek, J. Kercher, J. Widner, L. Asmar et al. „Abstract P1-10-03: A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy“. In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p1-10-03.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Kyroudis, Christos A., Dimitra D. Dionysiou, Eleni A. Kolokotroni, Jesper F. Kallehague, Kari Tanderup und Georgios S. Stamatakos. „Simulation of cervical cancer response to radiotherapy“. In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034637.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Zahra, Mark A. „445 Outcomes after radiotherapy for vulvar cancer“. In ESGO 2024 Congress Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/ijgc-2024-esgo.1046.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Milosavljević, Neda, Marija Živković Radojević, Darko Stojanović, Katarina Janković und Tatjana B. Miladinović. „A protocol for thoracic radiation therapy in patients with cardiac implantable electronic devices“. In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.193m.

Der volle Inhalt der Quelle
Annotation:
Prolonged lifespan and improved diagnostic and treatment modalities have led to significant progress in the diagnosis and treatment of cardiovascular disease and cancer. A substantial number of patients with malignancies also have cardiovascular disease at the time of cancer treatment. Per literature, over one million implantable cardiac devices are inserted annually. Ionizing radiation, especially in the thoracic area is related to cardiac implantable electronic device (CIED) damage and malfunction. Besides that, CIED can interfere with radiotherapy planning and delivery, as well as patient motivation to undergo radiotherapy treatment. Management of oncology patients, undergoing radiotherapy, for any indication, with a CIED is essential, and safe radiotherapy practice requires minimizing the risk to patients as much as possible, from pretherapy planning to posttherapy follow-up. A collaborative multidisciplinary approach, tailor-made for every single radiotherapy center is imperative to provide effective and safe radiotherapy for these patients. A collaboration of radiation oncologists, medical physicists and cardiologists from the University Clinical Center Kragujevac has created a local protocol for radiotherapy treatment and follow-up for patients receiving radiotherapy at the Center for Radiation Oncology University C linical Center Kragujevac, which provides safe and efficient delivery of an adequate radiotherapy dose to target volumes with appropriate cardiac monitoring.
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Cancer Radiotherapy"

1

Buchsbaum, Donald J. Genetic Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, Dezember 2003. http://dx.doi.org/10.21236/ada422767.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Li, Chuan-Yuan. Enhancement of Prostate Cancer Radiotherapy by Immunogenetherapy. Fort Belvoir, VA: Defense Technical Information Center, Februar 2004. http://dx.doi.org/10.21236/ada424647.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Silvia S. Jurisson, PhD. Rhodium-105 Bombesin Analogs for Prostate Cancer Radiotherapy. Office of Scientific and Technical Information (OSTI), Dezember 2005. http://dx.doi.org/10.2172/951630.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Charatsi, Dimitra, Polyxeni Vanakara, Michail Nikolaou, Aikaterini Evaggelopoulou, Dimitrios Korfias, Foteini Simopoulou, Nikolaos Charalampakis et al. Vaginal Dilator Use to Promote Sexual Wellbeing After Radiotherapy in Gynaecological Cancer Survivors: A Prospective Observational Study. Science Repository, Oktober 2021. http://dx.doi.org/10.31487/j.ijcst.2021.03.01.sup.

Der volle Inhalt der Quelle
Annotation:
Background: Since continuing advances in radiotherapy technology broaden the role of radiotherapy in the treatment of gynaecologic malignancies, the use of vaginal dilators has been introduced in order to mitigate the risk of vaginal stenosis. The main aims of this study were to investigate the vaginal dilator use efficacy in the treatment of radiation-induced vaginal stenosis and the vaginal dilator effect on sexual quality of life. Methods: We studied fifty-three patients with endometrial or cervical cancer. The participants were treated with radical or adjuvant external beam radiotherapy and/or brachytherapy. They were routinely examined at four time points post-radiotherapy when also they were asked to fill in a validated sexual function-vaginal changes questionnaire. A p-value less than 0.05 was considered statistically significant. Results: The vaginal stenosis grading score was decreased and the size of the vaginal dilator comfortably insertable was gradually increased throughout the year of vaginal dilator use while radiation-induced vaginal and sexual symptoms were improved throughout the year of VD use. All patients with initial grade 3 showed vaginal stenosis of grade 2 after 12 months of vaginal dilator use and 65.8% of the patients with grade 2 initial vaginal stenosis demonstrated final vaginal stenosis grade 1 while 77.8% of the participants with initial 1st size of vaginal dilators reached the 3rd vaginal dilator size after 12 months. Starting time of dilator therapy <= 3 months after the end of radiotherapy was associated with a significant decrease in vaginal stenosis. Additionally, there was an overall upward trend regarding patients’ satisfaction with their sexual life. Conclusion: Endometrial and cervical cancer survivors should be encouraged to use vaginal dilators for the treatment of vaginal stenosis and sexual rehabilitation after radiotherapy.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Guo, Jing, Yu han Chen, Chun xiao Li, Xiao Ling, Panpan Wang, Yuqing Yang und Yingying Zhang. Meta-analysis of Kangai injection combined with radiotherapy and chemotherapy in the treatment of gynecological malignant tumors. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juni 2022. http://dx.doi.org/10.37766/inplasy2022.6.0063.

Der volle Inhalt der Quelle
Annotation:
Review question / Objective: This study systematically evaluated the clinical efficacy and safety of Kangai injection combined with radiotherapy and chemotherapy in the treatment of gynecological malignant tumors. The subjects of the study were patients with clinical diagnosis of ovarian cancer, cervical cancer, and endometrial cancer. The experimental group was given Kang'ai injection combined with radiotherapy and chemotherapy, while the control group was given conventional chemotherapy. The primary outcome was the overall clinical response rate. Secondary outcomes included quality of life, body mass, indicators of immune function, and adverse events. Information sources: Eight databases including CNKI, Wan fang Database, VIP Chinese Database, China Biomedical Literature Service System, EI, Springer, PubMed, The Cochrane Library were searched before May 2022.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Rogers, Buck E. Enhanced Peptide Radiotherapy of Prostate Cancer Using Targeted Adenoviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, Juni 2004. http://dx.doi.org/10.21236/ada428235.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Chen, Lili. MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, Februar 2005. http://dx.doi.org/10.21236/ada435143.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Park, Jong Y. Genetic and Epigenetic Biomarkers for Recurrent Prostate Cancer After Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, Mai 2014. http://dx.doi.org/10.21236/ada609389.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Park, Jong. Genetic and Epigenetic Biomarkers for Recurrent Prostate Cancer After Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, Mai 2013. http://dx.doi.org/10.21236/ada581491.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Rogers, Buck E. Enhanced Peptide Radiotherapy of Prostate Cancer Using Targeted Adenoviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, Juni 2003. http://dx.doi.org/10.21236/ada420846.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Cancer Radiotherapy" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie